SCHEMBL30170441

SCHEMBL30170441

CC(C)C[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 1/20 0.44
EGFR P00533 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
BMP1 P13497 1/20 0.41
PTGS1 P23219 1/20 0.41
GSTK1 Q9Y2Q3 1/20 0.41
TASP1 Q9H6P5 1/20 0.40
CTSC P53634 1/20 0.39
NMT2 O60551 1/20 0.38
NMT1 P30419 1/20 0.38
FOLH1 Q04609 3/20 0.38
KEAP1 Q14145 2/20 0.37
NPY1R P25929 1/20 0.37
NPY2R P49146 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30170524 1.00 GLO1 (0.44) GLO1EGFRGRIN2DGRIN3BGRIN1
SCHEMBL30170446 0.95 EGFR (0.44) GLO1EGFRGRIN2DGRIN3BGRIN1
SCHEMBL31589113 0.93 FOLH1 (0.46) GLO1EGFRGRIN2DGRIN3BGRIN1
SCHEMBL30170535 0.91 OPRM1 (0.42) GLO1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29485672 0.90 FOLH1 (0.48) EGFRGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29485686 0.90 GRIN2D (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29789591 0.90 CTSC (0.43) GLO1EGFRPTGS1GSTK1CTSC
SCHEMBL30170575 0.89 OPRM1 (0.40) GLO1EGFRGRIN2DGRIN3BGRIN1
SCHEMBL8494001 0.88 GLO1 (0.49) GLO1BMP1PTGS1GSTK1FOLH1
SCHEMBL2804512 0.88 GLO1 (0.49) GLO1BMP1PTGS1GSTK1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149851-A2 METHODS FOR TREATING INFLAMMATORY DISEASES YUYU PHARMA, INC. (KR) 2025-07-17 WO claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US claimed
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU PHARMA, INC. (KR) 2023-05-11 US claimed
EP-4114430-A2 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU Pharma, Inc. (KR) 2023-01-11 EP claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-20230312648-A1 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES YUYU PHARMA, INC. (KR) 2023-10-05 US disclosed
US-11613558-B2 Peptides and pharmaceutical compositions for treating eye diseases YUYU PHARMA, INC. (KR) 2023-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312648-A1 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES VIP, IAPP, SCTR GLO1 4134/4885EGFR 189/4885GRIN2D 4766/4885
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS VIP, TSLP, IAPP GLO1 3781/4885EGFR 1464/4885GRIN2D 4737/4885
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient VIP, IAPP, NGLY1 GLO1 3708/4885EGFR 683/4885GRIN2D 4835/4885
US-11613558-B2 Peptides and pharmaceutical compositions for treating eye diseases VIP, IAPP, SCTR GLO1 4134/4885EGFR 189/4885GRIN2D 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.